{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:03:55Z","timestamp":1775027035357,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Gastric cancer (GC) patients from European (EU) and especially Latin American (LATAM) countries are underrepresented in previous large-scale multi-omic studies that have identified clinically relevant subgroups. The LEGACY study aimed to profile the molecular and immunological features of GCs from EU and LATAM countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Tumor biopsies from 95 EU and 56 LATAM GCs were profiled with immunohistochemistry (CD3, CD8, FOXP3, PD-L1, MSI and HER2), Nanostring mRNA expression analyses, and microbiome sequencing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Immune profiling identified four distinct immune clusters: a T cell dominant cluster with enriched activation pathways, a macrophage dominant cluster and an immune excluded microenvironment which were equally distributed among the countries. A fourth cluster of mostly Mexican patients consisted of excessive T cell numbers accompanied by enhanced cytokine signaling in absence of enhanced antigen presentation and cytotoxicity signatures and a strong association with <jats:italic>H. pylori<\/jats:italic> infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Both EU and LATAM countries have GCs with a T cell inflamed microenvironment that might benefit from checkpoint inhibition. We identified a highly inflamed GC subgroup that lacked antigen presentation and cytotoxicity associated with <jats:italic>H. pylori<\/jats:italic> CagA-positive strains, suggesting their contribution to tumor immune tolerance. Future studies are needed to unravel whether these cancers benefit from immunotherapy as well.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-025-02979-6","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:41:11Z","timestamp":1742503271000},"page":"783-792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence"],"prefix":"10.1038","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7749-929X","authenticated-orcid":false,"given":"Tessa S.","family":"Groen \u2013 van Schooten","sequence":"first","affiliation":[]},{"given":"Manuel","family":"Cabeza-Segura","sequence":"additional","affiliation":[]},{"given":"Rui M.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Carolina","family":"Mart\u00ednez-Ciarpaglini","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Barros","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Santos-Antunes","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Edith A.","family":"Fern\u00e1ndez-Figueroa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7394-5123","authenticated-orcid":false,"given":"Leonardo","family":"Lino-Silva","sequence":"additional","affiliation":[]},{"given":"Ang\u00e9lica Ixtaccihuatl","family":"Hernandez-Guerrero","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0446-123X","authenticated-orcid":false,"given":"Erika","family":"Ruiz-Garc\u00eda","sequence":"additional","affiliation":[]},{"given":"Carmelo","family":"Caballero","sequence":"additional","affiliation":[]},{"given":"Hugo","family":"Boggino","sequence":"additional","affiliation":[]},{"given":"Cinthia","family":"Gauna","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Cantero","sequence":"additional","affiliation":[]},{"given":"Berenice","family":"Freile","sequence":"additional","affiliation":[]},{"given":"Federico","family":"Esteso","sequence":"additional","affiliation":[]},{"given":"Juan","family":"O\u00b4Connor","sequence":"additional","affiliation":[]},{"given":"Arnoldo","family":"Riquelme","sequence":"additional","affiliation":[]},{"given":"Gareth","family":"Owen","sequence":"additional","affiliation":[]},{"given":"Erick","family":"Riquelme","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-8774","authenticated-orcid":false,"given":"Juan Carlos","family":"Roa","sequence":"additional","affiliation":[]},{"given":"Gonzalo","family":"Latorre","sequence":"additional","affiliation":[]},{"given":"Marcelo","family":"Garrido","sequence":"additional","affiliation":[]},{"given":"Fiorella","family":"Ruiz-Pace","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9473-0391","authenticated-orcid":false,"given":"Marc","family":"Diez Garc\u00eda","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Alsina","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[]},{"given":"Judith","family":"Farr\u00e9s","sequence":"additional","affiliation":[]},{"given":"Juan Antonio","family":"Carbonell-Asins","sequence":"additional","affiliation":[]},{"given":"Rossana","family":"Villagrasa","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Roos E.","family":"Pouw","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Jimenez-Mart\u00ed","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Miralles","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-318X","authenticated-orcid":false,"given":"Rodrigo","family":"Dientsmann","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-840X","authenticated-orcid":false,"given":"Ceu","family":"Figueiredo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-1006","authenticated-orcid":false,"given":"Fatima","family":"Carneiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3691","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Cervantes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-7457","authenticated-orcid":false,"given":"Sarah","family":"Derks","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2789-9082","authenticated-orcid":false,"given":"Tania","family":"Fleitas","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2979_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2979_CR2","unstructured":"Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2024. Available from: https:\/\/gco.iarc.who.int\/today\/en."},{"key":"2979_CR3","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8:e180\u2013e90.","journal-title":"Lancet Glob Health"},{"key":"2979_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/gutjnl-2017-314205","volume":"67","author":"RM Ferreira","year":"2018","unstructured":"Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67:226\u201336.","journal-title":"Gut"},{"key":"2979_CR5","first-page":"157","volume":"444","author":"M Mendes-Rocha","year":"2023","unstructured":"Mendes-Rocha M, Pereira-Marques J, Ferreira RM, Figueiredo C. Gastric Cancer: The Microbiome Beyond Helicobacter pylori. Curr Top Microbiol Immunol. 2023;444:157\u201384.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2979_CR6","unstructured":"Cancer of the Stomach - Cancer Stat Facts. 2024. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html."},{"key":"2979_CR7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"2979_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"2979_CR9","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384:1191\u2013203.","journal-title":"N Engl J Med"},{"key":"2979_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"2979_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"2979_CR12","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208.","journal-title":"Lancet"},{"key":"2979_CR13","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41416-022-02005-z","volume":"127","author":"M Cabeza-Segura","year":"2022","unstructured":"Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarc\u00f3n-Molero L, Gonz\u00e1lez-Vilanova A, et al. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Br J Cancer. 2022;127:2198\u2013206.","journal-title":"Br J Cancer"},{"key":"2979_CR14","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1136\/gutjnl-2014-308252","volume":"64","author":"SJ Lin","year":"2015","unstructured":"Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015;64:1721\u201331.","journal-title":"Gut"},{"key":"2979_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.annonc.2020.04.011","volume":"31","author":"S Derks","year":"2020","unstructured":"Derks S, de Klerk LK, Xu X, Fleitas T, Liu KX, Liu Y, et al. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann Oncol. 2020;31:1011\u201320.","journal-title":"Ann Oncol"},{"key":"2979_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1781333","volume":"9","author":"L Peng","year":"2020","unstructured":"Peng L, Qin BD, Xiao K, Xu S, Yang JS, Zang YS, et al. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncoimmunology. 2020;9:1781333.","journal-title":"Oncoimmunology"},{"key":"2979_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09689-9","volume":"22","author":"TS van Schooten","year":"2022","unstructured":"van Schooten TS, Derks S, Jim\u00e9nez-Mart\u00ed E, Carneiro F, Figueiredo C, Ruiz E, et al. The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. BMC Cancer. 2022;22:646.","journal-title":"BMC Cancer"},{"key":"2979_CR18","first-page":"25","volume":"58","author":"JR Siewert","year":"1987","unstructured":"Siewert JR, H\u00f6lscher AH, Becker K, G\u00f6ssner W. [Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg. 1987;58:25\u201332.","journal-title":"Chirurg"},{"key":"2979_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000470","volume":"4","author":"C Martinez-Ciarpaglini","year":"2019","unstructured":"Martinez-Ciarpaglini C, Fleitas-Kanonnikoff T, Gambardella V, Llorca M, Mongort C, Mengual R, et al. Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. ESMO Open. 2019;4:e000470.","journal-title":"ESMO Open"},{"key":"2979_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","volume":"140","author":"AN Bartley","year":"2016","unstructured":"Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140:1345\u201363.","journal-title":"Arch Pathol Lab Med"},{"key":"2979_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"2979_CR22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ijms21031096","volume":"21","author":"I Pinto-Ribeiro","year":"2020","unstructured":"Pinto-Ribeiro I, Ferreira RM, Pereira-Marques J, Pinto V, Macedo G, Carneiro F, et al. Evaluation of the Use of Formalin-Fixed and Paraffin-Embedded Archive Gastric Tissues for Microbiota Characterization Using Next-Generation Sequencing. Int J Mol Sci. 2020;21:1096.","journal-title":"Int J Mol Sci"},{"key":"2979_CR23","doi-asserted-by":"crossref","unstructured":"Edgar R. UNOISE2: improved error-correction for Illumina 16S and ITS amplicon sequencing. bioRxiv; 2016, https:\/\/www.biorxiv.org\/content\/10.1101\/081257v1.","DOI":"10.1101\/081257"},{"key":"2979_CR24","doi-asserted-by":"crossref","unstructured":"Edgar R. SINTAX: a simple non-Bayesian taxonomy classifier for 16S and ITS sequences. bioRxiv; 2016, https:\/\/www.biorxiv.org\/content\/10.1101\/074161v1.","DOI":"10.1101\/074161"},{"key":"2979_CR25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/nmeth.2604","volume":"10","author":"RC Edgar","year":"2013","unstructured":"Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10:996\u20138.","journal-title":"Nat Methods"},{"key":"2979_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"2018","unstructured":"Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B. 2018;57:289\u2013300.","journal-title":"J R Stat Soc Ser B"},{"key":"2979_CR27","doi-asserted-by":"publisher","first-page":"8099","DOI":"10.4049\/jimmunol.0900664","volume":"183","author":"CC Allison","year":"2009","unstructured":"Allison CC, Kufer TA, Kremmer E, Kaparakis M, Ferrero RL. Helicobacter pylori induces MAPK phosphorylation and AP-1 activation via a NOD1-dependent mechanism. J Immunol. 2009;183:8099\u2013109.","journal-title":"J Immunol"},{"key":"2979_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh0322","volume":"9","author":"J He","year":"2023","unstructured":"He J, Nascakova Z, Leary P, Papa G, Valenta T, Basler K, et al. Inactivation of the tumor suppressor gene Apc synergizes with H. pylori to induce DNA damage in murine gastric stem and progenitor cells. Sci Adv. 2023;9:eadh0322.","journal-title":"Sci Adv"},{"key":"2979_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br J Cancer"},{"key":"2979_CR30","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci USA. 2018;115:E4041\u2013e50.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2979_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15:307.","journal-title":"Cell Death Dis"},{"key":"2979_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00262-024-03675-9","volume":"73","author":"K-X Yu","year":"2024","unstructured":"Yu K-X, Yuan W-J, Wang H-Z, Li Y-X. Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion. Cancer Immunol, Immunother. 2024;73:115.","journal-title":"Cancer Immunol, Immunother"},{"key":"2979_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:127.","journal-title":"Signal Transduct Target Ther"},{"key":"2979_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02667-4","volume":"19","author":"V Pietrobon","year":"2021","unstructured":"Pietrobon V, Marincola FM. Hypoxia and the phenomenon of immune exclusion. J Transl Med. 2021;19:9.","journal-title":"J Transl Med"},{"key":"2979_CR35","doi-asserted-by":"publisher","first-page":"e002088","DOI":"10.1136\/jitc-2020-002088","volume":"9","author":"DP Zandberg","year":"2021","unstructured":"Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux K, Liu A, et al. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J Immunother Cancer. 2021;9:e002088.","journal-title":"J Immunother Cancer"},{"key":"2979_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880810","volume":"13","author":"B Janji","year":"2022","unstructured":"Janji B, Chouaib S. The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality? Front Immunol. 2022;13:880810.","journal-title":"Front Immunol"},{"key":"2979_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/gutjnl-2020-323392","volume":"71","author":"P Oster","year":"2022","unstructured":"Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C, et al. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2022;71:457\u201366.","journal-title":"Gut"},{"key":"2979_CR38","doi-asserted-by":"publisher","first-page":"e007699","DOI":"10.1136\/jitc-2023-007699","volume":"11","author":"PT Magahis","year":"2023","unstructured":"Magahis PT, Maron SB, Cowzer D, King S, Schattner M, Janjigian Y, et al. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2023;11:e007699.","journal-title":"J Immunother Cancer"},{"key":"2979_CR39","volume":"5","author":"K Jia","year":"2024","unstructured":"Jia K, Chen Y, Xie Y, Wang X, Hu Y, Sun Y, et al. Helicobacter pylori and immunotherapy for gastrointestinal cancer. Innovation. 2024;5:100561.","journal-title":"Innovation"},{"key":"2979_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1312","volume":"13","author":"Z Han","year":"2023","unstructured":"Han Z, Cheng S, Dai D, Kou Y, Zhang X, Li F, et al. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer. Clin Transl Med. 2023;13:e1312.","journal-title":"Clin Transl Med"},{"key":"2979_CR41","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","volume":"72","author":"W Fong","year":"2023","unstructured":"Fong W, Li Q, Ji F, Liang W, Lau HCH, Kang X, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis. Gut. 2023;72:2272\u201385.","journal-title":"Gut"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02979-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02979-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02979-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:06:07Z","timestamp":1745917567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02979-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5,18]]}},"alternative-id":["2979"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-02979-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MA discloses consultancy, advisory roles, honoraria from Amgen, AstraZeneca, Beigene, Drangofly Therapeutics, Jazz Pharmaceuticals, BMS, Lilly, Novartis and MSD. Institutional research funding from Merck. FL reports institutional grants from: Astra Zeneca, Beigene, BMS, Daiichi Sankyo and Gilead, and personal fees from: Amgen, ArtTempi. Astellas, Astra Zeneca, Bayer, Biontech, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Gilead, Elsevier, Incyte, Medscape, MedUpdate, Merck Serono, MSD, PAGE, Roche, Servier, StreamedUp!, VJ Oncology, all outside the submitted work. TF discloses advisory roles honoraria from Amgen, AstraZeneca, Beigene, BMS and MSD. Institutional research funding from Gilead. Speaker honoraria from Amgen, Servier, BMS, MSD, Lilly, Roche, Bayer. JF was full-time employee at Anaxomics Biotech at the time of the study. RD declares advisory role for Roche, Foundation Medicine, AstraZeneca received a speaker\u2019s fee from Roche, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp & Dohme, Lilly, AstraZeneca, Janssen, Takeda, Bristol Myers Squibb, GlaxoSmithKline, Gilead, research grants from Merck, Novartis, Daiichi-Sankyo, GlaxoSmithKline and AstraZeneca, and is investor in Trialing Health, S.L. AC declares institutional grants from Actuate Therapeutic Adaptimmune, Affimed, Amgen, Astellas Pharma, Astra Zeneca, Bayer, F. STAR Therapeutics, Genentech, Gilead, Janssen, Lilly, MedImmune, Merck Serono, MSD, Natera, Novartis, Ribon Therapeutics, Roche, Takeda. Speaker honoraria from Amgen, Foundation Medicine, Merck Serono, Roche. Advisory role for Abbvie, AnHeart Therapeutics, GSK, Merck Serono, Roche, Transgene, Amgen. Leadership role as ESMO president, ESMO OPEN Associate Editor, Annals of Oncology Associate Editor, and Cancer & treatment reviews, editor in chief. RMF and CF declares their own patent WO\/2018\/169423 on microbiome markers for gastric cancer. SD reports: a consultant or advisory role for BMS (related to checkpoint inhibitors); research funding, medication supply, or both from Incyte (related to checkpoint inhibitors); and speaker roles for Servier, BMS, and Benecke. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study has been conducted according to the principles of the Declaration of Helsinki (Fortaleza, Brazil, October 2013), following the Medical Research Involving Human Subjects Act and Good Clinical Practice standards. The study can be found under ClinicalTrials.gov Identifier: NCT04015466, and NCT03957031, July 11, 2019. The study protocol has been approved by the ethics committee of all patient-recruiting centres: the ethics committee of University Clinical Hospital of Valencia, Spain (reference number 2018\/205), the institutional review board of VU University Medical Center Amsterdam (reference number 2019.355. NL 69480.02919), the ethics committee of Instituto de Previsi\u00f3n Social, Asuncion-Paraguay (reference number CA N\u00b011-020\/19), the ethical research committee of Instituto Alexander Fleming, Buenos Aires Argentina (Resolution July 25th, 2019, for LEGACy study 1 and 2 and October 3rd, 2019 for LEGACy study 3); the ethical committee of Instituto Nacional de Cancerolog\u00eda (INCAN, M\u00e9xico (reference number INCAN\/CEI\/0486\/19). The ethics committee of the University Center of Sao Joao and Medicine Faculty of Porto University, Portugal (reference 100\/019), the scientific ethical Committee Pontificia University of Chili, reference 180806007, and the Drug research ethics committee of Valld\u2019Hebron University Hospital, Barcelona, Spain with references PR (AG)387\/2019 approved on October 29th, 2019 for LEGACy study 1, PR (AG)388\/2019 approved in December 13th 2019 for LEGACy study 2 and PR (AG)419\/2019 approved in January 30th, respectively. All participants provided written informed consent before study enrolment. Each data-contributing partner has undergone online ethical and data training before the beginning of data collection and has managed access to the data of their centre through this security system. Inside this system, a patient ID generator has generated a unique code for each participating patient to maintain data privacy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}